Summary
Global Markets Direct’s, ‘Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016’, provides in depth analysis on Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted pipeline therapeutics.
The report provides comprehensive information on the Brain Derived Neurotrophic Factor (Abrineurin or BDNF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Brain Derived Neurotrophic Factor (Abrineurin or BDNF)
- The report reviews Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Brain Derived Neurotrophic Factor (Abrineurin or BDNF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Brain Derived Neurotrophic Factor (Abrineurin or BDNF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
AudioCure Pharma GmbH
ReCyte Therapeutics Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) Overview 6
Therapeutics Development 7
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Stage of Development 7
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Therapy Area 8
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Indication 9
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Companies 12
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Universities/Institutes 14
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Companies Involved in Therapeutics Development 23
AudioCure Pharma GmbH 23
ReCyte Therapeutics Inc 24
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Drug Profiles 25
AC-002 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CNB-001 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Gene Therapy to Activate BDNF for Parkinson’s Disease - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
smilagenin - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Stem Cell Therapy for Ischemic Stroke - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Dormant Projects 33
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Featured News & Press Releases 34
Apr 10, 2015: Evidence of the efficacy of AC002 34
Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane 34
Feb 18, 2013: Phytopharm Announces Results From Parkinson’s Disease Clinical Trial Of Cogane 34
Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis 36
Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson’s Disease 36
Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis 37
Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study 38
Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis 39
Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status 40
Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease 40
Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane 41
Apr 20, 2009: Phytopharm Announces the Commencement of Clinical Study of Cogane in Patients with Parkinson’s disease 41
Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane 42
Jun 05, 2007: Phytopharm plc Presents Cogane Data At ‘11th International Congress Of Parkinson’s Disease And Movement Disorders’ 43
Nov 30, 2005: Phytopharm Announes That The Preliminary Trial Results Are Expected In December 2005 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by AudioCure Pharma GmbH, H2 2016 23
Pipeline by ReCyte Therapeutics Inc, H2 2016 24
Dormant Projects, H2 2016 33
List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21
